The Ocular Phenotype in Primary Hyperoxaluria Type 1.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
10 2019
Historique:
received: 05 02 2019
revised: 15 04 2019
accepted: 17 04 2019
pubmed: 13 5 2019
medline: 20 3 2020
entrez: 13 5 2019
Statut: ppublish

Résumé

To investigate ophthalmic features in a large group of patients with primary hyperoxaluria type 1 (PH1) and to determine the relation between ocular involvement and systemic disease severity. Retrospective, cross-sectional, multicenter study of the OxalEurope Registry Network. Sixty-eight patients with PH1 were included. Infantile PH1 was diagnosed in 12 patients, and non-infantile PH1 was diagnosed in 56 patients (17 with end-stage renal disease). Ophthalmic examination included best corrected visual acuity (BCVA) testing and multimodal retinal imaging, including fundus photography and optical coherence tomography (OCT). In selected cases, fundus autofluorescence imaging was performed. All eyes (n = 24) of infantile PH1 patients revealed severe retinal alterations and oxalate deposits, including macular crystals and hyperpigmentations (n = 9, 38%), and subretinal fibrosis (n = 15, 63%) with (n = 7, 47%) or without (n = 8; 53%) associated chronic retinal edema. In 9 eyes (38%, all with subretinal fibrosis), BCVA was significantly reduced (<20/50 Snellen equivalent). In contrast, all eyes (n = 112) of patients with non-infantile PH1 had a BCVA in the normal range (median, 20/20). Only 6 patients with non-infantile disease (11%, all with end-stage renal disease) showed mild, likely PH1-related retinal features. These deposits appeared as focal hyperreflective subretinal lesions on OCT imaging and were hyperautofluorescent on autofluorescence images. Severe ocular alterations occur in infantile cases, whereas mild or no ocular alterations are typical in non-infantile PH1 patients. The natural history of (sub)retinal oxalate deposits, the pathogenesis of subretinal fibrosis, and exact factors influencing the overall severity of ocular disease manifestation remain to be determined.

Identifiants

pubmed: 31078535
pii: S0002-9394(19)30218-1
doi: 10.1016/j.ajo.2019.04.036
pii:
doi:

Substances chimiques

Oxalates 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

184-191

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Johannes Birtel (J)

Department of Ophthalmology, University of Bonn, Bonn, Germany; Center for Rare Diseases Bonn (ZSEB), University of Bonn, Bonn, Germany.

Philipp Herrmann (P)

Department of Ophthalmology, University of Bonn, Bonn, Germany; Center for Rare Diseases Bonn (ZSEB), University of Bonn, Bonn, Germany.

Sander F Garrelfs (SF)

Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Department of Pediatric Nephrology, Amsterdam, The Netherlands; OxalEurope, The European Hyperoxaluria Consortium, Cologne, Germany.

Simon Dulz (S)

Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Yevgeniya Atiskova (Y)

Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Roselie M Diederen (RM)

Department of Ophthalmology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

Martin Gliem (M)

Department of Ophthalmology, University of Bonn, Bonn, Germany; Center for Rare Diseases Bonn (ZSEB), University of Bonn, Bonn, Germany; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, and Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.

Florian Brinkert (F)

Department of Pediatrics, University Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Frank G Holz (FG)

Department of Ophthalmology, University of Bonn, Bonn, Germany; Center for Rare Diseases Bonn (ZSEB), University of Bonn, Bonn, Germany.

Camiel J F Boon (CJF)

Department of Ophthalmology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.

Bernd Hoppe (B)

Center for Rare Diseases Bonn (ZSEB), University of Bonn, Bonn, Germany; OxalEurope, The European Hyperoxaluria Consortium, Cologne, Germany; Department of Pediatrics, Division of Pediatric Nephrology, University of Bonn, Bonn, Germany.

Peter Charbel Issa (P)

Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, and Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom. Electronic address: study-enquiry@outlook.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH